Prothena Corporation plc (NASDAQ:PRTA) Receives $23.75 Average Target Price from Brokerages

Posted by on Aug 29th, 2026

Shares of Prothena Corporation plc (NASDAQ:PRTA – Get Free Report) have received an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $24.5714.

Several brokerages recently commented on PRTA. Weiss Ratings downgraded shares of Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. UBS Group reissued a “buy” rating on shares of Prothena in a research note on Friday, July 24th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Prothena in a research report on Friday, July 24th. Citizens Jmp upped their target price on Prothena from $19.00 to $20.00 and gave the company a “market outperform” rating in a research note on Friday, May 8th. Finally, Citigroup reiterated an “outperform” rating on shares of Prothena in a report on Friday, May 8th.

Check Out Our Latest Analysis on Prothena

Insider Buying and Selling at Prothena

In other Prothena news, insider Anne Evans Kingston sold 7,662 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $8.47, for a total value of $64,897.14. Following the sale, the insider owned 55,782 shares in the company, valued at $472,473.54. This trade represents a 12.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Michael John Isaacs sold 8,386 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $8.47, for a total value of $71,029.42. Following the completion of the sale, the general counsel owned 35,745 shares in the company, valued at approximately $302,760.15. The trade was a 19.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have acquired 295,000 shares of company stock valued at $2,555,750 in the last quarter. 10.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Prothena

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rubric Capital Management LP grew its stake in Prothena by 36.0% in the 1st quarter. Rubric Capital Management LP now owns 5,000,000 shares of the biotechnology company’s stock worth $48,600,000 after acquiring an additional 1,322,669 shares in the last quarter. ADAR1 Capital Management LLC increased its position in shares of Prothena by 8.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,581,443 shares of the biotechnology company’s stock worth $15,372,000 after acquiring an additional 123,679 shares during the period. Renaissance Technologies LLC raised its stake in shares of Prothena by 39.5% during the first quarter. Renaissance Technologies LLC now owns 607,515 shares of the biotechnology company’s stock valued at $5,905,000 after acquiring an additional 172,000 shares in the last quarter. Focused Wealth Management Inc raised its stake in shares of Prothena by 93.0% during the first quarter. Focused Wealth Management Inc now owns 207,403 shares of the biotechnology company’s stock valued at $2,016,000 after acquiring an additional 99,924 shares in the last quarter. Finally, Penbrook Management LLC purchased a new stake in shares of Prothena in the first quarter valued at approximately $2,641,000. Institutional investors own 97.08% of the company’s stock.

Prothena Stock Up 2.6%

NASDAQ PRTA opened at $9.33 on Monday. Prothena has a 52 week low of $7.73 and a 52 week high of $11.80. The firm has a market capitalization of $488.43 million, a price-to-earnings ratio of -11.11, a PEG ratio of 3.20 and a beta of -0.30. The company has a fifty day moving average of $9.05 and a two-hundred day moving average of $9.39.

Prothena (NASDAQ:PRTA – Get Free Report) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.07. The business had revenue of $1.01 million for the quarter, compared to the consensus estimate of $0.42 million. Prothena had a negative net margin of 80.68% and a negative return on equity of 16.45%. Equities research analysts anticipate that Prothena will post 0.08 EPS for the current year.

Prothena Company Profile

(Get Free Report)

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.

Featured Stories

Analyst Recommendations for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.